The United Kingdom and the United States have concluded a major trade agreement that will maintain no levies on UK medicine shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise funding on medicines through the National Health Service (NHS). This move ensures that tariffs on these key products will be held at nothing for a timeframe of 36 months.
This agreement follows recent statements to hike tariffs on branded drug imports, with potential rates mentioned reaching 100%.
"This agreement with the Britain bolsters the international landscape for innovative medicines and introduces long-overdue balance to transatlantic drug exports," a statement said.
Economic Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the United States, which is easily the biggest destination for major UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK shipped medicines worth £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This deal safeguards work, boosts funding and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister remarked.
Detailed British Pledges
The deal includes several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to stay within budget will be limited at 15%. In the past, rebates topped 20%.
Broader Context
The pact takes place against a ongoing row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
This friction were exacerbated by claims that US consumers were paying a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while major investments have been directed toward US facilities.
One official acknowledged that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the previous ten-year period.
